Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02215265 · ClinicalTrials.gov registry record · Phase 3
Post-operative Adjuvant Treatment for HPV-positive Tumours (PATHOS)
A Phase 3 study of Human Papillomavirus (HPV)-Positive Oropharyngeal Cancer, sponsored by Lisette Nixon.
- Active
- Registry status
- Phase 3
- Development phase
- 1,269
- Enrollment target
- 20
- Study locations
NCT02215265: Active Phase 3 study of Human Papillomavirus (HPV)-Positive Oropharyngeal Cancer, sponsored by Lisette Nixon.
NCT02215265 is a Phase 3 study of Human Papillomavirus (HPV)-Positive Oropharyngeal Cancer that is active but no longer recruiting, run by Lisette Nixon. The registered enrollment target is 1,269 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (64% higher). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02215265, a Phase 3 study of Human Papillomavirus (HPV)-Positive Oropharyngeal Cancer, is active but no longer recruiting, sponsored by Lisette Nixon.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,269 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main objectives of the PATHOS study are: To assess whether swallowing function can be improved following transoral resection of HPV-positive OPSCC, by reducing the intensity of adjuvant treatment protocols. The aim is to personalise treatment, based on disease biology (HPV status and pathology findings), to optimise patient outcomes. To demonstrate the non-inferiority of reducing the intensity of adjuvant treatment protocols in terms of overall survival in the reduced intensity treatment arms.
Conditions Studied
Interventions
- DRUG Cisplatin
- RADIATION Postoperative radiotherapy
Study Locations (20)
Other
- Metro South Health - Brisbane
- Unicancer - Paris
- Vivantes Klinikum - Berlin
- Zentrum für Hals-, Nasen- und Ohrenheilkunde - Giessen
- Asklepios Kliniken - Hamburg
- Kath Marienkrankenhaus gGmbH - Hamburg
- Universitaetsklinikum des Saarlandes - Homburg
- Universitat Leipzig - Leipzig
- Ernst von Bergmann Klinikum - Potsdam
- Städtisches Klinikum Solingen - Solingen
- Universitätsklinikum Ulm - Ulm
- Royal United Hospitals Bath NHS Foundation Trust - Bath
- Queen Elizabeth Hospital - Birmingham
- Royal Blackburn Hospital - Blackburn
- Royal Sussex County Hospital - Brighton
- University Hospitals Bristol NHS Foundation Trust - Bristol
California
- Board of Trustees of the Leland Stanford Junior University - Redwood City
Florida
- Advent Health - Orlando
Texas
- MD Anderson Cancer Centre - Houston
Dorset
- University Hospitals Dorset NHS Foundation - Poole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,269 participants |
| Start Date | 2015-10 |
| Est. Completion | 2028-04 |
| Phase | Phase 3 |
What the registry record for NCT02215265 still lists
NCT02215265 is an interventional study that assigns participants to a tested intervention. Its 1,269 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (64% higher).
The record links to 1 condition, with Human Papillomavirus (HPV)-Positive Oropharyngeal Cancer appearing as the primary indexed condition, and to 2 interventions - of which Cisplatin is the first listed.
NCT02215265 names 20 study sites across 5 states, led by Other, California, Florida.
Frequently Asked Questions
What is clinical trial NCT02215265 about?
NCT02215265 is a clinical study titled "Post-operative Adjuvant Treatment for HPV-positive Tumours (PATHOS)". The main objectives of the PATHOS study are: To assess whether swallowing function can be improved following transoral resection of HPV-positive OPSCC, by reducing the intensity of adjuvant treatment protocols. The aim is to personalise treatment, based on disease biology (HPV status and pathology ...
What is the current status of trial NCT02215265?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,269 participants. The study started on 2015-10. Estimated completion is 2028-04.
What conditions does trial NCT02215265 study?
This clinical trial studies the following conditions: Human Papillomavirus (HPV)-Positive Oropharyngeal Cancer.
What interventions are being tested in trial NCT02215265?
The interventions under investigation include: Cisplatin (DRUG), Postoperative radiotherapy (RADIATION).
Who is sponsoring clinical trial NCT02215265?
This trial is sponsored by Lisette Nixon, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02215265 being conducted?
This trial has 20 study locations across California, Florida, Texas, Dorset. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02215265's enrollment target sits among peer trials
1,269 202nd of 2000 higher than 1,799 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06790641 · 1,270 participants · NA
Pathways to Perinatal Mental Health Equity
- NCT06876246 · 1,270 participants · NA
SBIR/ STTR Family Check-up Online
- NCT03678025 · 1,273 participants · Phase 3
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
- NCT06119581 · 1,264 participants · Phase 3
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia